Skip to main content

Advertisement

Table 1 Characteristics of the eligible studies included in the systematic assessment

From: Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer

Author and Year Study design Area Study arms Number of patients mPFS(m) mOS(m) ORR(%) DCR(%)
Higuchi K 2014 [10] phase III clinical trial Japan irinotecan+cisplatin 64 3.8 10.7 22.0 75.0
irinotecan 63 2.8 10.1 16.0 54.0
Nishikawa K 2015 [11] phase III clinical trial Japan irinotecan+cisplatin 82 4.6 13.9 17.0 69.0
irinotecan 81 4.1 12.7 16.0 65.0
Oba M 2011 [17] retrospective study Japan irinotecan+cisplatin 42 2.7 9.8 20.0 54.3
irinotecan 92 2.6 8 8.1 54.1
Satoh T 2015 [12] phase II clinical trial Japan and Korea irinotecan+nimotuzumab 40 2.4 8.3 18.4 47.4
irinotecan 43 2.8 7.7 10.3 46.2
Sym SJ 2013 [13] phase II clinical trial Korea irinotecan+ 5-fluorouracil 30 3 6.7 20.0 56.7
irinotecan 29 2.2 5.8 17.2 48.2
Tanabe K 2015 [14] phase II/III clinical trial Japan irinotecan+S1 145 3.8 8.8 9.0 48.0
irinotecan 148 3.4 9.5 9.0 53.0
Ueda A 2013 [16] retrospective study Japan irinotecan+mitomycin C 22 3.9 9.6 19.0 86.0
irinotecan 24 3.7 8.7 10.0 62.0